Home / Guidelines / Singapore outlines process to register biosimilars
Singapore outlines process to register biosimilars Posted 16/10/2009
Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Comparability studies between the biosimilar product and its reference product also must be submitted, the Health Sciences Authority says in the guidance posted on its website on 1 August 2009.
The guidance document describes the basic principles of a similar biological product, as well as the procedures and requirements for registration of a similar biological product. The document is intended to: The guidance document is adapted mainly from the EMEA guidelines on similar biological products, with consideration of Singapore’s local regulatory environment.
References: Guidance on registration of similar biological products in Singapore, August 2009.
FDAnews Drug Daily Bulletin Vol. 6 No. 188, 28 September 2009. Singapore outlines process to register biosimilars.
Source: FDAnews Drug Daily Bulletin
Comments (0)
Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!
Generics News Research General
- Italy asked to comply with marketing rules for...Generics/News | Posted 03/02/2012
- Generics market to experience strong growth in...Generics/Research | Posted 03/02/2012
- Generic and biosimilar user fee recommendations...Generics/News | Posted 03/02/2012
- Watson expands in Asia with Ascent PharmahealthGenerics/News | Posted 27/01/2012
Biosimilars News Research General
- Amphastar and Watson launch biosimilar enoxaparinBiosimilars/News | Posted 03/02/2012
- Production of 24 biosimilars in Iran by 2012Biosimilars/News | Posted 03/02/2012
- Factors affecting market access of biosimilarsBiosimilars/Research | Posted 03/02/2012
- Sandoz starts phase III trials for biosimilar f...Biosimilars/News | Posted 27/01/2012